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Results: 42 out of the total of 63 centres completed the 
survey (66.7%). 
At the time of completing the questionnaire: 
· 19 (45.2%) centres were using 4DCT and 33 (78.6%) were 
using PETCT for tumour delineation. 
· 21 (50%) centres were treating lung patients with intensity 
modulated radiation therapy. 
· All centres were using a type B treatment planning 
algorithm. 
· 11 (26.2%) centres were using respiratory gating or breath 
hold techniques. 
30 (71.4%) centres were using cone beam computed 
tomography for treatment verification. 
Conclusions: During the 5 years the Convert Trial has been 
open there have been significant advances in lung 
radiotherapy treatment technology. Major changes include 
the use of 4DCT and PET CT to aid tumour delineation, use of 
type B treatment planning algorithms, IMRT for treatment 
delivery and CBCT for treatment verification of patients with 
small cell lung cancer.  
The survey results show some international variation in 
techniques available for planning and treating CONVERT 
patients (data to be presented at the meeting). 
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Purpose/Objective: Most normal tissue complication 
probability (NTCP) models for Acute Esophageal Toxicity 
(AET) after (chemo-)radiotherapy for non-small cell lung 
cancer (NSCLC) are based on three-dimensional conformal 
radiotherapy (3D-CRT). Intensity-modulated radiation therapy 
(IMRT), however, has different dosimetric characteristics 
requiring new NTCP model parameters. Therefore, we 
investigated the relationship between clinical risk factors and 
dose-volume histogram (DVH) parameters to establish an 
IMRT-based multivariable NTCP model for AET. 
Materials and Methods: In 149 advanced stage NSCLC 
patients treated with IMRT, the AET scores were analyzed in 
relation to clinical risk factors and IMRT-plan derived DVH 
parameters. The NTCP model for grade ≥2 AET was selected 
by multivariable logistic regression analysis. Firstly, we 
evaluated the correlation between the clinical risk factors 
and DVH parameters to assess multicollinearities. Secondly, 
DVH data were fitted to the Lyman-Kutcher-Burman (LKB) 
dose-response model to establish the parameter values for n, 
m and D50. Thirdly, the optimal model (order) was 
determined by bootstrap sampling. We finally evaluated the 
performance of the multivariable NTCP model by the area 
under the curve (AUC) of the receiver operator characteristic 
and calibrated the model with the Hosmer and Lemeshow 
test for agreement between the predicted and observed 
NTCP estimates. 
Results: We found a strong correlation between esophageal 
Dmean and a wide range of esophageal DVH parameters (such 
as V15Gy through V60Gy) suggesting a high degree of 
multicollinearity. Dmean was associated with grade ≥2 AET on 
univariate logistic regression analysis (p=0.001). The LKB 
model parameter values were n = 1.04 (95% CI 0.48-5.49), m 
= 0.65 (0.27-1.03), and D50 = 32.84 (15.59-50.08) Gy. The 
volume parameter (n=1.04) indicates a large volume effect 
implying that Dmean is a good predictor for AET. For these 
reasons, Dmean was the only robust DVH parameter included in 
the multivariable logistic regression analysis. 
The NTCP model showed an increased risk of grade ≥2 AET 
with concurrent chemotherapy (CCR) (odds ratio (OR) 14.08, 
95% CI 4.70-42.18; p<0.001), with increasing Dmean (OR 1.12 
per Gy increase, 95% CI 1.06-1.19; p<0.001), in female 
patients (OR 3.33, 95% CI 1.36-8.12; p=0.008) and with tumor 
stage ≥T3 (OR 2.7, 95% CI 1.12-6.49; p=0.026). Discriminative 
power was good with an AUC of 0.84 (95% CI 0.771–0.912). 
There was no difference between the predicted complication 
risk and the observed outcome (p=0.127), indicating that the 
model is well calibrated. 
Conclusions: A multivariable predictive model including the 
parameters CCR, Dmean, tumor stage and gender has a high 
predictive value for grade ≥2 AET after IMRT for advanced 
stage NSCLC. Validation of this model in an independent 
patient cohort is mandatory.  
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Purpose/Objective: Single-photon emission computed 
tomography (SPECT) can potentially be used to define 
functional lung regions (FL), but it remains unclear how the 
radiation dose to FL is related to the risk of radiation-induced 
lung toxicity after radiotherapy. The purpose of the study 
was to analyse dosimetric parameters in functional and non-
functional lung determined by SPECT, and to establish their 
role in risk of symptomatic lung toxicity after curative 
radiotherapy  
Materials and Methods: Patients undergoing definitive 
chemo-radiotherapy for non-small cell lung cancer were 
included prospectively. Perfusion SPECT/CT was performed 
before the treatment started. Regions of interest 
corresponding to 20, 40, 60 and 80% of maximum perfusion 
count (FL 20-80%) were created on SPECT and transferred to 
the planning CT (Figure 1). Functional dose-volume 
histograms (DVHf) for FL 20-80% were created. Primary 
clinical end-point was radiation pneumonitis (RP) graded by 
CTC-AE version 4. Functional DVH was compared with 
conventional DVH (DVHc). Association of DVHf parameters and 
functional mean lung dose (MLDf) for FL 20-80% with 
symptomatic radiation pneumonitis (CTC grade 2-5) was 
assessed.  
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Results: Seventy-one consecutive patients were prospectively 
included in the study. Baseline patient, tumour and 
treatment characteristics are presented in Table 1. 
Preliminary analysis of the first 34 patients with baseline 
SPECT/CT scans showed no association with radiation 
pneumonitis for conventional MLD, whereas there was an 
association with symptomatic radiation pneumonitis for MLD 
to FL 40%. MLDf was larger than MLDc in 13 out of 34 patients 
with a difference of around 5 Gy. All 13 patients developed 
symptomatic RP. Analysis of functional DVH parameters for 
the whole patient cohort is underway. 
 
 
 
Conclusions: Our preliminary analysis shows that SPECT-
determined functional MLD is more associated with the risk of 
symptomatic radiation pneumonitis than total 
MLD.Therefore, functional dosimetric parameters from SPECT 
may be useful in future studies to guide radiotherapy 
treatment planning, in order to reduce the risk of radiation-
induced pulmonary symptoms 
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Purpose/Objective: Intensity Modulated Radiotherapy (IMRT) 
allows dose to be sculpted around target volumes, 
maintaining dose to the tumour whilst reducing dose to 
normal tissues. However, uptake of IMRT for lung cancer 
remains low, as a result of the paucity of clinical data and 
concerns about the impact of the low dose bath on toxicity. 
The Christie has treated 650 lung cancer patients with IMRT 
since 2008. Here we report the results of 106 patients, 
focusing on toxicity. Survival will be reported at a later date. 
Materials and Methods: A retrospective review of the first 
106 patients receiving 6MV inversely planned (6-8 field) Step 
and Shoot IMRT for lung cancer from 2008-2012 was carried 
out. A database was interrogated to correlate planning 
parameters with toxicity.  
Results: 106 patients with a median age of 67 (36-85) were 
included. Patients received a dose of 50-68 Gy in 20-33 
fractions. Seventy three (69%) had non-small cell lung cancer, 
23 (22%) small cell lung cancer, 3 (3%) mixed histology and 6 
(6%) no histology. At presentation, 2 (2%), 17 (16%), 82 (77%) 
and 4 patients (4%) had stage I, II, III and IV disease. 
Treatment modalities were split evenly between concurrent 
(36%), sequential (33%) chemo-radiotherapy and radiotherapy 
alone (31%).  
Mean PTV volume was 586 cc (113.7-1297.2). Mean lung V20, 
V10 and V5 were 27.9% (7.9-35.3), 50.9% (13.4-83.1) and 
64.8% (17.9-98.9). Fifty-two patients (49%) had V5 values > 
65%. Mean dose to the oesophagus was 2462 cGy (482-5102); 
oesophageal V55 and V35 were 4.2% (0-70.8) and 37.6% (0-
79.8). Heart V30 and V5 were 23.5% (0-60.6) and 57.6% (1.7-
100). 
Acute G3 pneumonitis and oesophagitis were observed in 4 
(3.8%) and 18 (17.1%) patients respectively. Late toxicity was 
not available in all patients. 5/76 (6.8%) developed late G3 
pneumonitis and G3 dyspnoea, late G2 cough was reported in 
7/75 (9.7%). Grade 1 and 2 pulmonary fibrosis occurred in 
35/86 (41%) and 4/86 (5%) patients. Oesophageal stricture 
was evident in 3/83 (4%) and 1 patient developed an 
oesophageal fistula.  
There was no significant correlation between lung V5 and 
acute or late lung toxicity, using >65% as a cut off. Similarly, 
